Sector Gamma AS Acquires Shares of 24,967 Icon Plc $ICLR

Sector Gamma AS bought a new stake in Icon Plc (NASDAQ:ICLR) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 24,967 shares of the medical research company’s stock, valued at approximately $4,369,000.

Other institutional investors have also modified their holdings of the company. CIBC Asset Management Inc lifted its holdings in shares of Icon by 42.2% during the third quarter. CIBC Asset Management Inc now owns 2,064 shares of the medical research company’s stock worth $361,000 after purchasing an additional 613 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Icon in the 3rd quarter worth $1,342,000. New Wave Wealth Advisors LLC purchased a new stake in shares of Icon in the third quarter valued at about $246,000. Hudson Edge Investment Partners Inc. increased its stake in shares of Icon by 12.4% during the third quarter. Hudson Edge Investment Partners Inc. now owns 200,739 shares of the medical research company’s stock worth $35,129,000 after acquiring an additional 22,164 shares during the period. Finally, Osborne Partners Capital Management LLC lifted its position in Icon by 2.7% in the third quarter. Osborne Partners Capital Management LLC now owns 51,590 shares of the medical research company’s stock valued at $9,028,000 after purchasing an additional 1,342 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on ICLR. Leerink Partners restated an “outperform” rating on shares of Icon in a research report on Monday, January 5th. Truist Financial reiterated a “hold” rating and issued a $222.00 price objective (down previously from $231.00) on shares of Icon in a research note on Thursday, January 8th. UBS Group set a $220.00 target price on shares of Icon in a research report on Friday, October 24th. TD Cowen lifted their price target on shares of Icon from $172.00 to $183.00 and gave the company a “hold” rating in a research report on Thursday. Finally, Bank of America lowered Icon from a “buy” rating to a “neutral” rating and set a $195.00 price target on the stock. in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $200.60.

Icon Stock Performance

Shares of NASDAQ ICLR opened at $186.70 on Friday. The company has a market cap of $15.08 billion, a PE ratio of 25.26, a price-to-earnings-growth ratio of 3.93 and a beta of 1.26. Icon Plc has a 12 month low of $125.10 and a 12 month high of $211.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The company has a 50-day simple moving average of $181.38 and a 200-day simple moving average of $175.36.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.